JP2017523789A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523789A5
JP2017523789A5 JP2017506395A JP2017506395A JP2017523789A5 JP 2017523789 A5 JP2017523789 A5 JP 2017523789A5 JP 2017506395 A JP2017506395 A JP 2017506395A JP 2017506395 A JP2017506395 A JP 2017506395A JP 2017523789 A5 JP2017523789 A5 JP 2017523789A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
polypeptide
subject
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017506395A
Other languages
English (en)
Japanese (ja)
Other versions
JP6723982B2 (ja
JP2017523789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/043792 external-priority patent/WO2016022671A1/en
Publication of JP2017523789A publication Critical patent/JP2017523789A/ja
Publication of JP2017523789A5 publication Critical patent/JP2017523789A5/ja
Application granted granted Critical
Publication of JP6723982B2 publication Critical patent/JP6723982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017506395A 2014-08-06 2015-08-05 インターロイキン−2/インターロイキン−2受容体アルファ融合タンパク質および使用方法 Active JP6723982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06
US62/033,726 2014-08-06
PCT/US2015/043792 WO2016022671A1 (en) 2014-08-06 2015-08-05 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020108721A Division JP7272663B2 (ja) 2014-08-06 2020-06-24 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法

Publications (3)

Publication Number Publication Date
JP2017523789A JP2017523789A (ja) 2017-08-24
JP2017523789A5 true JP2017523789A5 (https=) 2018-09-13
JP6723982B2 JP6723982B2 (ja) 2020-07-15

Family

ID=53836871

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017506395A Active JP6723982B2 (ja) 2014-08-06 2015-08-05 インターロイキン−2/インターロイキン−2受容体アルファ融合タンパク質および使用方法
JP2020108721A Active JP7272663B2 (ja) 2014-08-06 2020-06-24 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法
JP2023069282A Pending JP2023099045A (ja) 2014-08-06 2023-04-20 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020108721A Active JP7272663B2 (ja) 2014-08-06 2020-06-24 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法
JP2023069282A Pending JP2023099045A (ja) 2014-08-06 2023-04-20 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法

Country Status (32)

Country Link
US (3) US12084483B2 (https=)
EP (2) EP4438621A3 (https=)
JP (3) JP6723982B2 (https=)
KR (1) KR102653758B1 (https=)
CN (2) CN107074967B (https=)
AU (3) AU2015301071C1 (https=)
BR (1) BR112017001940A2 (https=)
CA (1) CA2957273C (https=)
CL (1) CL2017000284A1 (https=)
CO (1) CO2017002166A2 (https=)
DK (1) DK3177307T3 (https=)
EA (2) EA035956B1 (https=)
ES (1) ES2986097T3 (https=)
FI (1) FI3177307T3 (https=)
HR (1) HRP20241258T1 (https=)
HU (1) HUE068478T2 (https=)
IL (2) IL250007B (https=)
LT (1) LT3177307T (https=)
MA (2) MA40094B1 (https=)
MX (1) MX388977B (https=)
MY (1) MY180831A (https=)
PE (1) PE20170503A1 (https=)
PH (1) PH12017500042A1 (https=)
PT (1) PT3177307T (https=)
RS (1) RS65930B1 (https=)
SA (1) SA517380842B1 (https=)
SG (2) SG10201913695PA (https=)
SI (1) SI3177307T1 (https=)
SM (1) SMT202400414T1 (https=)
TN (1) TN2017000020A1 (https=)
WO (1) WO2016022671A1 (https=)
ZA (1) ZA201700245B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
KR102042246B1 (ko) 2014-02-06 2019-11-28 에프. 호프만-라 로슈 아게 인터류킨-2 융합 단백질 및 이의 용도
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
EP3458485B1 (en) * 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CA3084262A1 (en) * 2017-12-06 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to il-2
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019183389A1 (en) * 2018-03-23 2019-09-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
JP7464530B2 (ja) * 2018-03-28 2024-04-09 ブリストル-マイヤーズ スクイブ カンパニー インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法
EP3941935A1 (en) 2019-03-18 2022-01-26 Biontech Cell & Gene Therapies Gmbh Interleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
JP2022533254A (ja) * 2019-05-24 2022-07-21 プロヴィヴァ セラピューティクス (ホン コン) リミテッド Il-2組成物およびその使用方法
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
CA3146156A1 (en) * 2019-07-12 2021-01-21 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
MX2022000991A (es) * 2019-07-25 2022-05-24 Univ Chicago Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
US20220378933A1 (en) * 2019-09-19 2022-12-01 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
MX2022004577A (es) * 2019-10-18 2022-05-10 Alkermes Pharma Ireland Ltd Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune.
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US11597753B2 (en) 2020-04-30 2023-03-07 Immune Targeting, Inc. Activatable IL2 composition and methods of use
KR20230050389A (ko) * 2020-08-13 2023-04-14 브리스톨-마이어스 스큅 컴퍼니 Il-2를 관심 표적 세포로 재지시하는 방법
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
CN118891055A (zh) * 2022-02-11 2024-11-01 穆拉肿瘤公司 用于癌症免疫疗法的组合物和方法
WO2023159135A2 (en) * 2022-02-16 2023-08-24 University Of Miami Il-2 and tl1a fusion proteins and methods of use thereof
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
EP4669671A1 (en) * 2023-02-22 2025-12-31 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ANTI-IL2RA ANTIBODIES AND THEIR USES
WO2025207491A1 (en) * 2024-03-25 2025-10-02 Mural Oncology, Inc. Compositions and methods for cancer immunotherapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE69530107T2 (de) 1994-12-28 2003-10-16 University Of Kentucky, Lexington Monoklonaler anti-idiotypischer antikörper 3h1 aus maus
US6967092B1 (en) * 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
JPWO2003029475A1 (ja) 2001-09-28 2005-01-20 株式会社ディナベック研究所 エピトープ結合β2mをコードする哺乳動物細胞感染性ウイルスベクターおよびその利用
BRPI0508470A (pt) 2004-03-05 2007-07-31 Chiron Corp sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
EP3263581B2 (en) * 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
CN101255197B (zh) 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EP2553101A4 (en) 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
WO2012088383A2 (en) 2010-12-23 2012-06-28 Genentech, Inc. PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME
RS61391B1 (sr) * 2012-06-08 2021-02-26 Alkermes Pharma Ireland Ltd Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Similar Documents

Publication Publication Date Title
JP2017523789A5 (https=)
FI3177307T3 (fi) Interleukiini-2/interleukiini-2-reseptori alfa-fuusioproteiinit ja niiden käyttömenetelmät
US12285462B2 (en) pH-triggered membrane peptide-mediated epitope tethering at cell surfaces
DK2633865T3 (en) USE OF INTERLEUKIN-22 IN THE TREATMENT OF VIRAL HEPATITIS
RU2017101436A (ru) Mic-1 слитные белки и их применение
JP2014525901A5 (https=)
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
HRP20161450T1 (hr) Stabilizirana varijanta aktivinskog receptora iib
RU2014135053A (ru) Иммуногены для вакцинации против вич
CN109689086A (zh) 具有延长的血清半衰期的融合蛋白
JP2015524413A5 (https=)
CN107698684A (zh) 包含突变的免疫球蛋白Fc部分的GLP‑1融合蛋白
JP2014510519A5 (https=)
JP2015511599A5 (https=)
CN121319219A (zh) Il2突变蛋白
RU2010141916A (ru) Растворимый мутант рецептора фактора некроза опухоли
JP2016019527A (ja) B細胞活性化因子の拮抗物質、その調製方法及び利用法
AU2024288570A1 (en) Designed interleukin-2 cytokine compositions and methods for use
JP6431476B2 (ja) オステオプロテゲリン由来の組成物およびその使用
CN116375880A (zh) 融合蛋白及其制备方法和应用
Wei et al. Cloning and characterization of goose interleukin-17A cDNA
US20100055135A1 (en) Enhancin of hepatitis b virus vaccine and its gene
CN117384298A (zh) 一种快速规模化生产病毒样颗粒疫苗或药物的方法
CN113956346A (zh) 一种重组白介素-15变体
CN103145854A (zh) 重组Tβ4-BP5融合肽、基因、工程菌及应用